STOCK TITAN

Seres Therapeutics: DesRosier sells 103 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Seres Therapeutics, Inc. EVP and Chief Legal Officer Thomas DesRosier reported two restricted stock unit transactions of 133 and 111 units on November 15, 2026, alongside the acquisition of 244 common shares. He sold 103 shares on November 16, 2026, at $1.38 per share. The sale was made under a Rule 10b5-1 instruction adopted March 2, 2023, solely with the intent to cover taxes in connection with restricted stock unit vesting.

Insider DesRosier Thomas
Role See Remarks
Sold 103 shs ($142.14)
Approx. gross sale proceeds $142.14
Type Security Shares Price Value
Sale Common Stock F2 103 $1.38 $142.14
Exercise Restricted Stock Units F1, F3 133 $0.00 $0.00
Exercise Restricted Stock Units F1, F4 111 $0.00 $0.00
Exercise Common Stock F1 244 -- --
Holdings After Transaction: Restricted Stock Units — 688 units (Direct); Common Stock — 8,258 shares (Direct)
Footnotes (4)
  1. F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  3. F3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  4. F4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Common shares sold 103 shares November 16, 2026
Sale price $1.38 per share Sale on November 16, 2026
Restricted stock units 133 units Reported for November 15, 2026
Restricted stock units 111 units Reported for November 15, 2026
Common shares acquired 244 shares November 15, 2026
Rule 10b5-1 instruction regulatory
"the sales reported were effected pursuant to a Rule 10b5-1 instruction"
restricted stock units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MCRB shares did Thomas DesRosier sell, and at what price?

Thomas DesRosier sold 103 shares of Seres Therapeutics common stock on November 16, 2026, at $1.38 per share. The sale was made under a Rule 10b5-1 instruction adopted March 2, 2023, solely with the intent to cover taxes in connection with restricted stock unit vesting.

How many MCRB restricted stock units were reported as settled?

Two restricted stock unit transactions, for 133 and 111 units, were reported on November 15, 2026, along with acquisition of 244 common shares. Each restricted stock unit represents a contingent right to receive one share of Seres Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DesRosier Thomas

(Last)(First)(Middle)
C/O SERES THERAPEUTICS, INC.
101 CAMBRIDGE PARK DRIVE

(Street)
CAMBRIDGE MASSACHUSETTS 02140

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/15/2026M244A(1)8,361D
Common Stock11/16/2026S(2)103D$1.388,258D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)11/15/2026M133 (3) (3)Common Stock133$0132D
Restricted Stock Units(1)11/15/2026M111 (4) (4)Common Stock111$0556D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Remarks:
EVP and Chief Legal Officer
/s/ Thomas J. DesRosier11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading